Bethany Sensenig

Executive

Director

Supernus Pharmaceuticals, Inc.9 Meters Biopharma, Inc.Alpha Cognition Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 1 saleSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (2 ops.)

€205k

Latest filing published 17 Apr 2026 for Alpha Cognition Inc.. Read the official filing

Filing timeline

BuySale

Bethany Sensenig

Insider track record

Disclosed buys

Disclosed sells

Signal history

Bethany Sensenig: trading record in brief

Bethany Sensenig is a declared insider at 3 companies (senior executive); the most frequent names are Supernus Pharmaceuticals, Inc., 9 Meters Biopharma, Inc. and Alpha Cognition Inc. The record holds 6 filings, for trades running from 27 March 2023 to 16 April 2026.

Sales make up the whole of the open-market record (2 sales, €205k). The rest of the record consists of 3 share grants and 1 option exercise.

Most recently, on 17 April 2026, the filings show a share grant in Alpha Cognition Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.